1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Benralizumab (Asthma) - Forecast and Market Analysis to 2023

Benralizumab (Asthma) - Forecast and Market Analysis to 2023

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, “Benralizumab (Asthma) - Forecast and Market Analysis to 2023”. The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.

AstraZeneca’s benralizumab is a humanized immunoglobulin G1 (IgG1) mAb targeting the interleukin-5 receptor alpha subunit (IL-5Ra), which results in antibody-dependent cell-mediated cytotoxicity that induces apoptosis, leading to eosinophil and basophil depletion. It has been shown that reducing eosinophilic inflammation decreases the frequency and severity of asthma exacerbations (Haldar et al., 2009). There is relatively long-lasting depletion of peripheral blood eosinophils after either IV or SC administration of benralizumab; in particular, this effect persisted for at least two to three months in individuals receiving doses ranging from 0.03-3mg/kg (Busse et al., 2010).

Scope

- Overview of Asthma, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Benralizumab including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Benralizumab for the top eight countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Asthma
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Benralizumab performance
- Obtain sales forecast for Benralizumab from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia)

Table Of Contents

Benralizumab (Asthma) - Forecast and Market Analysis to 2023
1 Table of Contents

2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 9
2.3 Upcoming Related Reports 11
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 14
3.1.3 Prognosis 16
3.1.4 Quality of Life 16
3.2 Symptoms 17
4 Disease Management 18
4.1 Diagnosis and Treatment Overview 18
4.1.1 Diagnosis 18
4.1.2 Treatment Guidelines, Clinical Practice, and Leading Prescribed Drugs 19
4.1.3 Clinical Practice 21
5 Competitive Assessment 26
5.1 Overview 26
5.2 Strategic Competitor Assessment 28
6 Unmet Need and Opportunity 32
6.1 Overview 32
6.2 Personalized Therapies to Control Severe Asthma 33
6.2.1 Unmet Need 33
6.2.2 Gap Analysis 34
6.2.3 Opportunity 34
6.3 Better Patient Compliance 34
6.3.1 Unmet Need 34
6.3.2 Gap Analysis 35
6.3.3 Opportunity 36
6.4 Lower Cost of Asthma Medications 36
6.4.1 Unmet Need 36
6.4.2 Gap Analysis 37
6.4.3 Opportunity 37
6.5 Proper Diagnosis of Asthma in Children 37
6.5.1 Unmet Need 37
6.5.2 Gap Analysis 38
6.5.3 Opportunity 38
7 Pipeline Assessment 39
7.1 Overview 39
7.2 Promising Drugs in Clinical Development 41
8 Benralizumab 43
8.1 Overview 43
8.2 Efficacy 44
8.3 Safety 45
8.4 Dosing and Formulation 45
8.5 Potential Clinical Positioning 45
8.6 Potential Commercial Positioning 46
8.7 Pricing and Reimbursement 46
8.8 SWOT Analysis 47
8.9 Forecast 47
9 Appendix 49
9.1 Bibliography 49
9.2 Abbreviations 55
9.3 Methodology 57
9.4 Forecasting Methodology 57
9.4.1 Diagnosed Asthma Patients 57
9.4.2 Percent Drug-Treated Patients 58
9.4.3 General Pricing Assumptions 58
9.4.4 Generic Erosion 59
9.4.5 Pricing of Pipeline Agents 59
9.5 Physicians and Specialists Included in This Study 60
9.6 About the Authors 63
9.6.1 Author 63
9.6.2 Author/Reviewer 63
9.6.3 Reviewer 64
9.6.4 Global Head of Healthcare 65
9.7 About GlobalData 66
9.8 Disclaimer 66

1.1 List of Tables

Table 1: Symptoms of Asthma 17
Table 2: Treatment Guidelines for Asthma by Country 19
Table 3: Most Prescribed Drugs for Asthma by Class and Disease Severity in the Global Markets, 2013 20
Table 4: Dosing of Common ICSs for Adult Asthma Therapy to Achieve Equivalent Therapeutic Potency 23
Table 5: Recommended Low Daily Dose of ICSs in Children with Asthma Under Five Years of Age 25
Table 6: Leading Treatments for Asthma, 2014 31
Table 7: Unmet Need and Opportunity in Asthma 32
Table 8: Asthma - Late Stage Pipeline, 2014 41
Table 9: Product Profile - Benralizumab 44
Table 10: Efficacy of Benralizumab Versus Placebo 45
Table 11: Benralizumab SWOT Analysis, 2014 47
Table 12: Global Sales Forecast ($) for Benralizumab, 2013-2023 48
Table 13: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 62

1.2 List of Figures

Figure 1:Stepwise Disease Management Approach for Asthma in Adults 22
Figure 2: Stepwise Disease Management Approach for Asthma in Children Age Five and Younger 24
Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in Asthma, 2013-2023 42

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.